Skip to content

Search

Showing results for "early lung health"

Custom Medicine for Kids

Thanks to an enabling donation from the Stan Perron Charitable Foundation, The Kids Research Institute Australia is home to one of the first paediatric personalised medicine research centres in the world.

Gender Equity, Diversity, and Inclusivity

At The Kids, we don’t just accept difference — we celebrate it, and we support it for the benefit of our employees and our community.

Meningococcal disease

Meningococcal disease is caused by the bacteria Neisseria meningitidis, or 'meningococcus'. It's an uncommon but very serious disease that can result in death.

Big run ends, race for cure continues

Our local legend, brain cancer researcher Jacob Byrne, has crossed the finish line of his final marathon, completing his Big Run for Little Brains - 30 marathons in 30 days, covering 1266km across Perth’s local government areas.

Our services

CliniKids provides therapy support and individualised programs to help children and families to reach their full potential.

Relationship between The Kids Research Institute Australia and Wangle

Understand the relationship between The Kids Research Institute Australia and Wangle Family Insites, a research-driven app to analyse children’s online activity in real time.

Laboratory Technologies

Within the Institute, we have a commitment to the highest standards of research with pro-active staff ensuring the lab environment is safe and secure.

WA children with most aggressive cancers to benefit from Australian-first personalised medicine clinical trial

Personalised medicine for childhood cancers in West Australia is a step closer thanks to the Zero Childhood Cancer program’s state clinical trial launched today

Finding new treatments for rare brain cancers in infants

The WA Kids Cancer Centre has secured $1.1 million in funding from the Medical Research Future Fund’s (MRFF) Paediatric Brain Cancer Research Stream 2 to develop more effective and less toxic treatments for rare brain cancers in infants.

A surgically optimized intraoperative poly(I:C)-releasing hydrogel prevents cancer recurrence

Recurrences frequently occur following surgical removal of primary tumors. In many cancers, adjuvant therapies have limited efficacy. Surgery provides access to the tumor microenvironment, creating an opportunity for local therapy, in particular immunotherapy, which can induce local and systemic anti-cancer effects.